In vitro susceptibility of Candida species isolated from blood to common antifungal agents in a Spanish tertiary medical centre
Abstract number: P2165
Alkorta M., Hernandez-Almaraz J., Eraso E., Quindós G.
Objectives: To evaluate the susceptibilities of Candida blood isolates to common antifungal agents in the Hospital de Cruces, a Spanish tertiary medical centre.
Methods: A total of 206 blood isolates of different species of Candida were collected in the clinical routine in the period January 2004October 2007. The yeasts were identified by conventional mycological methods. In vitro susceptibilities to 5-fluorocytosine (5FC), amphotericin B (AMB), fluconazole (FLC), itraconazole (ITC), ketoconazole (KTC), and voriconazole (VRC) were determined using the Etest method. MICs were recorded after 24 h of incubation at 37 °C.
Results: The most frequently isolated species was Candida parapsilosis (87 isolates, 42.2%) followed by Candida albicans (79 isolates, 38.3%). Other non-C. albicans species, such as Candida tropicalis (17 isolates, 8.3%), Candida glabrata (10 isolates, 4.9%), Candida guilliermondii (7 isolates, 3.4%), or Candida krusei (4 isolates, 1.9%), were recovered in minor frequency. MICs at which 90% of the clinical isolates were inhibited were 0.5 mg/L for 5FC, 1 mg/L for AMB, 4 mg/L for FLC, 0.38 mg/L for ITC, 0.094 mg/L for KTC and 0.125 mg/L for VRC. AMB, VRC and KTC were very active in vitro against all blood isolates, even those that were resistant to ITC or FLC. A total of 23 isolates (11.2%) showed decreased susceptibility to ITC (MIC > 0.25 mg/L) and 10 isolates (4.9%) showed decreased susceptibility to FCZ (MIC > 8 mg/L). FLC resistance (32 mg/L) was limited to 4 C. krusei isolates and to one isolate each of C. glabrata and C. guilliermondii. ITC resistance (2 mg/L) was limited to 3 C. glabrata isolates, 2 C. guilliermondii, 2 C. tropicalis and 1 C. krusei.
Conclusions: Scarce antifungal resistances were found in Candida blood isolates from our institution. FLC resistance was limited to 4 C. krusei isolates and to one isolate each of C. glabrata and C. guilliermondii.
Funding: Projects PI061895 from Fondo de Investigación Sanitaria (Ministerio de Sanidad y Consumo of Spain) and IT-22207 from Departamento de Educación, Universidades e Investigación (Gobierno Vasco).
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|